Free press releases distribution network?

Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3 - AnaSpec, EGT Group is pleased to offer Eurogentec’s popular monoclonal antibody, anti-5-methylcytidine (Clone 33D3) for use in epigenetics research - AnaSpec.com
AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2012/05/29 - AnaSpec, EGT Group is pleased to offer Eurogentec’s popular monoclonal antibody, anti-5-methylcytidine (Clone 33D3) for use in epigenetics research - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Purified from ascites, this IgG1 / λ isotype antibody is supplied as a 1 mg/ml solution (in PBS) and is available in three sizes (0.1 mg, 0.5 mg and 1 mg).
5-Methylcytidine (5-MeCyd) is cytosine modified by methylation on the fifth position of the cytidine ring. This modification occurs naturally in the DNA of plants and vertebrate. DNA methylation is a post-replication process involved in the establishment of genomic imprinting, in the control of gene expression and of differentiation. Alterations of DNA methylation pattern are associated with carcinogenesis. A global DNA hypomethylation is often detected in tumor tissues, associated with local hypermethylation sites. Since this antibody discriminates between the modified base, 5-MeCyd and its normal counterpart, cytosine, it is a useful tool for gene promoter methylation analysis.

The most published anti-5-Methylcytidine antibody available on the market, anti-5-Methylcyidine from Clone 33D3 can be used in applications such as Methylated DNA Immunoprecipitation (MeDIP), MeDIP-on-chip assay, immunofluorescence, flow cytometry and immunohistochemistry. Histopathological analysis of tissue samples can be performed without having to destroy cells through DNA extraction procedures.

This antibody has been used to detect alterations in the urinary excretion of nucleosides from cancer patients, to visualize the distribution of methyl-rich regions along human chromosomes, to quantify in situ differences between normal and malignant cells from peripheral blood as well as on tissue sections.

AnaSpec, EGT Group

AnaSpec, Eurogentec Group (anaspec.com) is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today